Moreover, FADS1 and FADS2 are two rate-controlling enzymes in de novo fatty acid synthesis and TG metabolism, and the two genes are potential targets therapeutic targets for NAFLD disease [62, 63], serving as pivotal fatty acid desaturases in the process of de novo lipogenesis and ensuing steatosis within goose liver [64]. This evidence concerns the gene FADS1 and metabolic dysfunction-associated steatotic liver disease.